Dr. Rohit Arora

Chicago, Illinois

Medical Licensures, Certifications, and Awards

Over the course of his long career, Dr. Rohit Arora has acquired a number of medical licenses, certifications, and awards. These licenses, certifications, and awards speak to the fact that Dr. Arora is completely and utterly committed to taking care of his patients and solving their various health-related issues.

Medical Licensures and Certifications

Diplomat, American Subspecialty Board of Cardiovascular Disease, 1985 – Certificate
Diplomat, American Board of Internal Medicine, 1983 – Certificate

Federal License Examination (FLEX), New York, 1982
Educational Council Foreign Medical Graduate

Doctor of Medicine (MD), University of Bombay, 1981
Bachelor of Medicine & Surgery (MBBS), University of Bombay, 1976

New York Medical License
Nuclear Regulatory Commission License (Eligible)

Illinois State License
New Jersey Medical License

Honors, Awards, Prizes

Dean’s Award, Pathology, Medical School, University of Bombay Special Award Pathology, Medical School, University of Bombay Best Resident

BYL Nair Hospital, University of Bombay, 1981 Best Resident, Joint Diseases, North General Hospital, NY, 1983 Editorial Board, Medical Crossfire

Consultant, Archives of Internal Medicine, Chest, Journal of American College of Cardiology

Reviewer, American Journal of Cardiology

Reviewer, Catheterization and Cardiovascular Disease

Reviewer, Catheterization and Cardiovascular Interventions

Reviewer, Heart

Member, Editorial Board, Journal of Cardiovascular Pharmacology and Therapeutics Reviewer, Journal of Postgraduate Medicine

Reviewer, Journal of Critical Illness

Trainee Award, Southern Section, American Federation for Clinical Research, Southern Society Clinical Investigation

Nomination for Golden Apple Award for Dedication and Excellence in Teaching Students, University of Medicine / Dentistry of New Jersey, New Jersey Medical School Student Council, 2001

Faculty Development Award, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Department of Medicine, 2002

Nomination for Golden Apple Award for Dedication and Excellence in Teaching Students, University of Medicine & Dentistry of New Jersey, New Jersey Medical School Student Council, 2002

Faculty Research Award, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Department of Medicine, 2002

Selection of Cardiology Fellow -2002 Laennec Society Young Clinician Award at the American Heart Association Scientific Sessions, 2002, Chicago, IL

“Enhanced External Counterpulsation (EECP) for Stable but Severe Angina” at the American College of Cardiology Foundation’s 35th Annual New York Cardiovascular Symposium, December 15, 2002

Alternate Councilor IL-ACC Board

Panel Member, System Devices Advisory Committee, to the Center for Devices and Radiological Health by the Food and Drug Administration.

Co-Chairman “Meet the Experts” Session of “Treatment of Refractory Angina Pectoris” at the American College of Cardiology 52nd Annual Scientific Session, 2003, Chicago, IL

Sponsor, The Stanley J. Sarnoff Endowment for Cardiovascular Science Fellowship, Gauri Tilak, “Quantitative Analysis of Regional Systolic Function in Hypertrophic Cardiomyopathy with Gadolinium Enhancing Abnormalities,” 2002-2003

Selected as International Health Professional of the Year 2003, Research and Advisory Board International Biographical Centre of Cambridge, England

Co-Chairman “Meet the Experts” Session of “The Non-Revascularizable Patient” at the American College of Cardiology 53rd Annual scientific session, Orlando, FL, 2004

Co-Chairman “Meet the Experts” Session of “Enhanced External Counterpulsation Clinical Research Implications” at the AC of Cardiology, 53rd Annual Scientific Session, Florida, 2004

Symposium Director, Cardiovascular Disease in South Asians Symposium – Chicago Medical School, North Chicago, IL, December 2005

Vice President, American Heart Association Board North Jersey Chapter

Max Harry Weil Excellence in Teaching Award, Rosalind Franklin University, Chicago Medical School, Department of Medicine, North Chicago, IL, 2005-2006

Excellence in Education Award, North Chicago VA Medical Center, North Chicago, IL, 2005-2006

Member – Association of Black Cardiologists (ABC)

Reviewer – Clinical Cardiology

Reviewer – Diabetes Care

Reviewer – Lancet

Member – Council of Clinical Cardiology AHA

Member – Council of Atherosclerosis AHA

Fellow – American Heart Association Council, Arteriosclerosis, Vascular Disease Editorial Board, Clinical Cardiology

Reviewer – International Journal of Cardiology

Reviewer – European Journal of Cardiology

Reviewer – Circulation

Reviewer – Journal of the Renin Angiotensin Aldosterone System (JRAAS) Reviewer – Indian Journal of Medicine

Reviewer – ACTA Pharmacological Sinita

Reviewer – American Journal of Psychiatry

Senator at Large, Department of Medicine, The Chicago Medical School Rosalind Franklin University of Medicine and Science, North Chicago, IL

Reviewer – Indian Journal of Medical Research

Member, Editorial Board – American Journal of Therapeutics Reviewer- Biomedical Central

Member, Editorial Board – Journal of the CardioMetabolic Syndrome

Consultant, Circulatory System Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food & Drug Administration

Consultant, Circulatory System Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration.

Member, Editorial Board – Journal of the Biologics: Targets and Therapy

Board Member European Society of Cardiology 2000

IRB Member North Chicago VA Medical Center and Hines VA Medical Center

Reviewer Diabetes

Editorial Board – Heart International

Editor-in-Chief – Heart International

First Place Award at Loyola University/ Rosalind Franklin University and Medical Center/ Hines Veterans’ Administration Medical Center/ Captain James A. Lovell Federal Health Care Center

Research Day Poster Presentation. “Post-traumatic Stress Disorder Is Associated With Increased Incidence Of Insulin Resistance And Metabolic Syndrome.” Naser Ahmadi MD PhD1, Rohit Arora MD1,

Rachel Yehuda PhD2, Ramin Ebrahimi MD3, Nutan Vaidya MD1

Editor-in-Chief – Who Is Publishing in My Domain

Editoral Board Member – Journal Pragmatic and Observational Research

Editoral Board – Journal of Cardiac Pharmaology and Therapeutics

Editoral Board – Annals of Chronic Diseases

Editoral Board –Cardiovascular & Hematological Disorders-Drugs Targets

Departmental and University Committees

Inter-Intensive Care Unit Committee, Columbia Presbyterian Medical Center Cardiac Outcomes Committee, Columbia Presbyterian Medical Center Cardiology Fellowship Committee, Columbia Presbyterian Medical Center

Task Force on Enhancement of Residency Training, Columbia Presbyterian Medical Center

Committee for Conscious Sedation, Presbyterian Hospital

Committee for Critical Pathways, Department of Medicine, Cardiology Division, Columbia Presbyterian Medical Center

Committee for Joint Research Activities, Columbia Presbyterian Medical Center & St. Francis Hospital

Member, Society of Practitioners of the Columbia Presbyterian Medical Center Pharmacy and Therapeutics Committee, Columbia Presbyterian Medical Center Cardiopulmonary Arrest Committee, Columbia Presbyterian Medical Center

Cardiovascular Operations Committee, University of Medicine and Dentistry of New Jersey

Pharmacy and Therapeutics Committee, University of Medicine and Dentistry of New Jersey

Committee for Cardiology University Health System Consortium, University of Medicine & Dentistry-New Jersey

Graduate Medical Education Committee, University of Medicine and Dentistry of New Jersey

Continuing Medical Education Committee, University of Medicine and Dentistry of New Jersey

Operative and Invasive Procedure Review Committee, University of Medicine and Dentistry of New Jersey

Invasive & Other Procedures Review Committee, University of Medicine and Dentistry of New Jersey

Dignitary Protection Plan Committee, University of Medicine and Dentistry of New Jersey

Member Executive Committee, Chicago Medical School, Illinois

Member Senior Executive Committee, Department of Medicine, Chicago Medical School

Member, Residency and Fellowship Committee, North Chicago VA Medical Center

Member Subcommittee the Chicago Medical School’s Strategic Plan 2006-2010-Key Strategy III

Chair, Research Committee, Department of Medicine Chicago Medical School Member, Residency Appeals Board, Chicago Medical School

Chicago Medical School, 3rd and 4th year, Medical Student Curriculum Subcommittee. Chicago Medical School, Vertical Integration Committee, Chairman

Studies and Grants

Associate Investigator – Mount Sinai-New York University Reperfusion Trial. Principal Investigator: KP Rentrop, 1984 – 1986.

Associate Investigator – Thrombolysis in Myocardial Infarction (TIMI-IIB) Trial. Principal Investigator: H. Mueller, 1986 – 1987.

Associate Investigator – A multicenter, double-blind, randomized study to compare the safety and efficacy of BG8967 with Heparin in Patients with unstable angina undergoing Percutaneous Transluminal Coronary Angioplasty, PTCA. Principal Investigator: L. Rabbani, 1994-1995.

Principal Investigator – Coumadin Aspirin Trial in Myocardial Infarction Study (CARS), Grant support – $120,000.

Principal Investigator – A multicenter, randomized, parallel, double-blind study to investigate the safety and clinical efficacy of MK-383 alone and MK-383 in combination with Heparin vs. Heparin alone in patients with high-risk, unstable angina/non-Q-wave myocardial infarction. Protocol/study 011. 1994-1996. Grant support – $120,000.

Principal Investigator – A multicenter, randomized, parallel, double-blind study to investigate the safety and clinical efficacy of MK-383 alone and MK-383 in combination with Heparin vs. Heparin alone in patients with high-risk, unstable angina/non-Q-wave myocardial infarction during PTCA.94-96. Protocol/study 2006.  Grant support – $120,000.

Principal Investigator – Thrombogenic factors and recurrent coronary events. 1994- 1995. NIH grant.

Principal Investigator – Enhanced external counterpulsation research study in coronary artery disease. 1994-1996. Grant support – $75,000.

Principal Investigator – Determinants of the time of Myocardial Infarction Onset – Part II: Modifiers of Myocardial Infarction Onset. 1996 – 1998. Grant support – $10,000

Principal Investigator – Prevention of events with angiotensin converting enzyme inhibitor therapy. 1996-1998. Grant support – $40,000.

Principal Investigator – A double-blind, placebo-controlled, multinational trial to investigate the effect of the Na /H Exchange Inhibitor HOE642 (Cariporide) on all-cause mortality and myocardial infarction in patients with acute coronary syndrome related to the disease process or to an interventional cardiac procedure. 1997-1999. Grant support – $40,000.

Associate Investigator – A two-year study of cardio-vascular disorders in elders and impairments in daily functioning and other qualities of life. 1997. Grant support – $50,000.

Co-Principal Investigator – Severity adjusted outcomes for AMI. 1997-1999. Grant support -$50,000.

Associate Investigator – Corlopam prevention of contrast dye nephropathy study. 1999, Grant support – $20,000.

Principal Investigator-Enhanced external counterpulsation(EECP)in heart failure study (pivotal study). 2000. Grant support – $90,000.

Principal Investigator-Pharmacokinetic study of enoxaparin in patients undergoing percutaneous coronary intervention (8-12 hours after subcutaneous injection). Lovenox study (PEPCI). 2000. Grant support – $25,000

Associate Investigator-Rapid risk stratification of unstable angina patients to suppress adverse outcomes with early implementation of the ACC/AHA Guidelines: The CRUSADE National Quality Improvement Initiative Study. 2001. Grant support – $35,000.

Co-Investigator-Randomized, double-blind, placebo controlled study to assess dose of Simvastatin needed to reach the desired level of LDL-C according to the National NCEP­ATPII. 2001. Grant support – $75,000.

Randomized, Multinational, multicenter, double-blind, placebo-controlled, two arm parallel group trial of rimonabant 20mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors. Sanof-Aventis: Clinical Research: Grant Support $30,000.

Co-Investigator-Compare dosing and therapeutic effect of Atorvastatin to Simvastatin in achieving established LDL-C goals. 2001. Grant support – $150,000.

Site Principal Investigator for UMDNJ, Principal cardiologist of a randomized clinical drug trial comparing two drugs, Warfarin and Aspirin, in the prevention of stroke in patients. NIH Grant – $21,797,694 (National PI Dr. Patrick Pelucni) – April 1, 2001 – March 31, 2003.

Principal Investigator – Does ACT guided use of dalteparin offer significant clinical benefit in percutomeous coronary intervention? 2003 – $3,500.

Associate Investigator – Safety and Efficacy of Enoxaparin in PCI patients, and international randomized evaluation (Steeple): Sponsored Aventis.

Principal Investigator – A double-blind, randomized, placebo-controlled parallel – group study of randomized SR at a dose of 1000 mg twice a day in patients with angina who remain symptomatic on Amlodipine: Cardiovascular Therapeutics.

Evaluation of coronary blood flow and regulation via transmyocardial ventricular assist device in sheep-PI – Ken Khaw.

A long-term, open-label, safety extension study of the combination of fenofibric acid and statin therapy for subjects with mixed dyslipiemia. Abbott Laboratories – Protocol M05-758, Version 1.

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and simvastatin combination therapy to fenofibric acid and simvastatin monotherapy in subjects with mixed dyslipidemia. Abbott Laboratories – Protocol M05-749.

Randomized double evaluation of L-T Anticoagulant therapy comparing the efficacy and safety of 2 blind doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular afib (RE-LY). 06-017.

Associate Investigator: A phase 3, active (Warfarin) controlled, randomized, double- blind parallel arm study to evaluate efficacy and safety of apixaban in preventing stroke and systemic embolism in subjects with nonvalvular atrial fibrillation.

Aristotle: Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation. Protocol CV1 85030. 01-06.

Principal Investigator: Action Registry. Acute coronary treatment and intervention outcome network.

Randomized evaluation of long term anticoagulant therapy comparing the efficacy and safety of two blinded doses of Dabigatran Etexilate w/ open label Warfarin for the prevention of stroke & systemic embolism in patients with non-valvular atrial fibrillation (RE-LY) Boehringer-Ingelheim Protocol IRB 06-0 17.

Randomized, multinational, multicenter, double-blind, placebo-controlled, two arm, parallel group trial of rimonabant 20 mg QD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors –

CRESCENDO. Sanofi Aventis. Protocol IRM 07-048.

Medication habits of patients using CV drugs. Protocol IRM 07-061.

Apixaban versus acetylsalicylic acid (ASA) to who have failed or are unsuitable for vitamin k antagonist treatment: A randomized double-blind trial (CV1 8 50-48). Bristol Myers Squibb. Protocol 07-095.

An eight-week randomized, double-blind, parallel group, multicenter, forced titration study to evaluate the efficacy and safety of Aliskiren HCTZ versus Aliskiren Monotherapy in metabolic syndrome patients with stage two hypertension #CSPP 1 00A24 10. Novartis.

RELY-ABLE long term multicenter extension of Dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomized trial to assess the effect of a knowledge translation intervention on patient outcomes. BIPI (pending).

A randomized double-blind placebo-controlled parallel group study of the efficacy and safety of four administrations of XRP0038/NV1FGF 4 mg at 2-week intervals on amputation or any death in critical limb ischemia patients with skin lesions. EFC6 145. Sanofi-Aventis (pending).

A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated Idraparinux with oral adjusted doses Warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation. Protocol EFC 10295. Sanofi­Aventis (pending).

A randomized, double-blind, placebo-controlled, parallel-group, study on the use of Ranolazine in the prevention of recurrence of atrial fibrillation. CV Therapeutics (pending).

Withdrawal from statins and risk for cardiovascular events (pending)

First Place Award at Loyola University/ Rosalind Franklin University and Medical Center/ Hines Veterans’ Administration Medical Center/ Captain James A. Lovell Federal Health Care Center Research Day Poster Presentation.  “Post-traumatic Stress Disorder Is Associated With Increased Incidence Of Insulin Resistance And Metabolic Syndrome.”  Naser Ahmadi MD PhD1, Rohit Arora MD1, Rachel Yehuda PhD2, Ramin Ebrahimi MD3, Nutan Vaidya MD1

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial) Protocol # AMR-01-01-0019

GLORIA – AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III) Protocol #1160.129

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults Shire Protocol #HGT-FIR-096:

A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome

[985555-2] Cardiovascular Inflammation Recution Trial (CIRT): A Randomized Double-blind, Placebo Controlled Event Driven trial of Weekly Low Dose Methotrexate in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease

[985566-2] Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study Principal Investigator: Rohit Arora, MD

[1043058-1] Prominent: Pemafibrate to reduce cardiovascular outcomes by reducing trigilycerides in patient with diabetes. Protocol K-877-302 Principal Investigator: Rohit Arora

[1167998-0014] MC Prospective Rndmzd DB Placebo Cntrl Parallel Grp Study to Eval Effect of AMR101 on Cardiovascular Health and Mortality Principal Investigator: Rohit Arora

[1173295-0015] GLORIA-AF Global Registry on Long Trerm Oral Anti thrombotic in Patients with Atrial Fibrillation (Phase ll/lll) Protocol 1160.129 Principal Investigator: Dr. Rohit Arora

[1186978-0018] Cardiovascular Inflammation Recution Trial(CIRT): A Randomized Double-blind, Placebo Controlled Event Driven trial of Weekly Low Dose Methotrexate in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients with Type 2 Diabetes or Metabolic Syndrome. Principal Investigator: Dr. Rohit Arora

[1188745-0019] Study interventions for managing patients with chronic Leukemia in chronic phase: The 5 Year Prospective Cohort Study Principal Investigator: Rohit Arora

[1198102-0020] Prominent: Pemafibrate toreduce Cardiovascular outcomes by reducing Triglycerides in patients with diabetes Protocol K-877-302 Principal Investigator: Rohit Arora

[1199406-0021] The Influenza Vaccine to Effectively stop Cardio Thoracic events and Decompensated Heart Failure(Invested)Trial Principal Investigator: Rohit Arora